Trial Profile
A Multicenter, Open label, Non-controlled Study in Patients with Relapsed/Refractory Multiple Myeloma
Status:
Not yet recruiting
Phase of Trial:
Phase II
Latest Information Update: 07 Dec 2021
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary) ; Dexamethasone; Pomalidomide
- Indications Multiple myeloma
- Focus Therapeutic Use
- Sponsors Ono Pharmaceutical
- 29 Jan 2018 New trial record